Key result
First semaglutide dose linked to transient intestinal ischemia as a rare gastrointestinal adverse effect.
Why the study?
Wegovy is typically well tolerated for managing obesity, but gastrointestinal adverse effects occur and only 1 case of Wegovy-induced transient intestinal ischemia has been documented.
Highlights a rare but severe vascular adverse effect (transient intestinal ischemia) associated with semaglutide initiation.
Alerts clinicians to rare ischemia at semaglutide initiation; extends sparse reports but leaves causality and incidence open.
Obesity is a global health issue that impacts millions of people worldwide. Semaglutide is a glucagon-like peptide-1 receptor agonist that was initially developed as a treatment for type 2 diabetes mellitus under the brand name Ozempic. Additional studies showed semaglutide at larger doses (marketed as Wegovy) to be an effective medication for weight management. Wegovy for managing obesity is typically well tolerated; however, there have been reports of gastrointestinal adverse effects. Only 1 case of Wegovy-induced transient intestinal ischemia has been documented, making it extremely unusual. Here, we report the case of a 50-year-old man who experienced transient intestinal ischemia following his first Wegovy dosage.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2025) studied this question. A 50-year-old man experienced transient intestinal ischemia after his first dose of Wegovy, highlighting a rare gastrointestinal adverse effect of semaglutide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: